GenixPharmaceucticals Corporation Cash Flow-to-Debt Ratio
GenixPharmaceucticals Corporation cash flow-to-debt ratio. GenixPharmaceucticals Corporation (GENX) has a Cash Flow-to-Debt Ratio of -0.01x as of April 2026, meaning its operating cash flow of CA$-16.30K could theoretically repay 0% of its total liabilities (CA$1.58 Million) in one year. Check how high is GenixPharmaceucticals Corporation's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GenixPharmaceucticals Corporation (2015–2025)
Cash flow-to-debt ratio of GenixPharmaceucticals Corporation from 2015 to 2025. Historical debt coverage capacity for GenixPharmaceucticals Corporation across 11 annual periods. Check GenixPharmaceucticals Corporation cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
GenixPharmaceucticals Corporation Cash Flow-to-Debt Ratio by Year (2015–2025)
GenixPharmaceucticals Corporation cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for GenixPharmaceucticals Corporation. For the full cash flow conversion analysis, see GENX cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.08x | CA$-124.07K | CA$1.47 Million | ▲ +44.7% |
| 2024 | -0.15x | CA$-187.34K | CA$1.23 Million | ▲ +6.0% |
| 2023 | -0.16x | CA$-220.67K | CA$1.36 Million | ▲ +22.2% |
| 2022 | -0.21x | CA$-219.58K | CA$1.05 Million | ▲ +63.3% |
| 2021 | -0.57x | CA$-428.31K | CA$755.19K | ▼ -42.5% |
| 2020 | -0.40x | CA$-195.03K | CA$489.88K | ▲ +44.0% |
| 2019 | -0.71x | CA$-58.55K | CA$82.41K | ▼ -326.9% |
| 2018 | 0.31x | CA$34.18K | CA$109.15K | ▲ +1013.5% |
| 2017 | -0.03x | CA$-9.35K | CA$272.80K | ▲ +98.6% |
| 2016 | -2.43x | CA$-165.07K | CA$68.04K | ▲ +40.6% |
| 2015 | -4.09x | CA$-452.55K | CA$110.78K | — |